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Abstract
The incidence of breast cancer is increasing in the Western world and there is an urgent need for studies of the mechanisms
of sex steroids in order to develop novel preventive strategies. Diet modifications may be among the means for breast
cancer prevention. Angiogenesis, key in tumor progression, is regulated by the balance between pro- and anti-angiogenic
factors, which are controlled in the extracellular space. Sampling of these molecules at their bioactive compartment is
therefore needed. The aims of this study were to explore if tamoxifen, one of the most used anti-estrogen treatments for
breast cancer affected some of the most important endogenous angiogenesis regulators, vascular endothelial growth factor
(VEGF), angiogenin, and endostatin in normal breast tissue in vivo and if a diet supplementation with flaxseed had similar
effects as tamoxifen in the breast. Microdialysis was used for in situ sampling of extracellular proteins in normal breast tissue
of women before and after six weeks of tamoxifen treatment or before and after addition of 25 g/day of ground flaxseed to
the diet or in control women. We show significant correlations between estradiol and levels of VEGF, angiogenin, and
endostatin in vivo, which was verified in ex vivo breast tissue culture. Moreover, tamoxifen decreased the levels of VEGF and
angiogenin in the breast whereas endostatin increased significantly. Flaxseed did not alter VEGF or angiogenin levels but
similar to tamoxifen the levels of endostatin increased significantly. We conclude that one of the mechanisms of tamoxifen
in normal breast tissue include tipping of the angiogenic balance into an anti-angiogenic state and that flaxseed has limited
effects on the pro-angiogenic factors whereas the anti-angiogenic endostatin may be modified by diet. Further studies of
diet modifications for breast cancer prevention are warranted.
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Introduction
Long-term exposure to sex steroids such as estradiol and/or
progesterone increases the risk of breast cancer [1,2]. However,
the patho-physiological mechanisms behind this increase are still
not fully understood. Angiogenesis is a key factor in tumor
development and progression [3]. In the female reproductive
organs sex steroids are potent regulators of angiogenesis, a process
necessary for normal function of these tissues. The breast is also a
sex steroid dependent tissue suggesting a potential role for
hormonal regulation of angiogenesis of this tissue as well.
One key angiogenic factor, vascular endothelial growth factor
(VEGF), has been shown to be estrogen regulated in normal breast
tissue [4,5] and in breast cancer [6,7,8]. Another potent pro-
angiogenic factor is angiogenin a 14.2 kD polypeptide member of
the RNase A superfamily, which induces endothelial cell
proliferation after its nuclear translocation [9,10,11]. The nuclear
translocation of angiogenin is also necessary for the angiogenic
response of VEGF, and other angiogenesis regulators [10]. We
have recently shown that angiogenin is estrogen regulated in a
similar fashion as VEGF in normal breast tissue and experimental
breast cancer [4,5,12]. However, angiogenesis is regulated by the
balance between pro- and anti-angiogenic factors and endostatin is
one important endogenous anti-angiogenic protein. Human
endostatin is a 20-kDa proteolytic fragment of the C-terminal
domain NC1 of collagen XVIII, which inhibits endothelial cell
proliferation and migration, and induces apoptosis in proliferating
endothelial cells [13,14,15]. Endostatin may also down-regulate
the VEGF/VEGFR signaling pathway by a direct action on tumor
tissue cells, or up-regulate other anti-angiogenic genes [16]. We
have previously shown that estradiol down-regulates and tamox-
ifen up-regulates endostatin generation in experimental breast
cancer via effects on matrix metalloproteinase activity [17,18,19].
As the incidence of breast cancer is increasing in the Western
world there is an urgent need for studies of the mechanisms of sex
steroids and anti-estrogens on normal breast tissue in order to
develop new preventive strategies for this disease. The anti-
estrogen tamoxifen has been shown to reduce the incidence of
breast cancer by more than 40%, but this therapy may induce
severe side effects such as endometrial cancer and thromboembo-
lism [20,21,22]. Diet may be another preventive strategy. In
Eastern societies, where the diet contains large amounts of
phytoestrogens, the incidence of breast cancer is low and migrant
studies support that lifestyle factors rather than genetics affect the
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25720risk [23,24]. One class of phytoestrogen is lignans, which are found
in high amounts in flaxseed. In majority of epidemiological studies,
dietary plant lignans or their enterolignan metabolites have been
associated with reduced breast cancer risk [25].
In the present study we determined if a diet of flaxseed or
treatment with tamoxifen affected potent angiogenic regulators in
normal human breast tissue in vivo.
Materials and Methods
Subjects
The regional ethical review board of Linko ¨ping approved the
study and all women gave their oral informed consents. Written
informed consent is not mandatory by the ethical vetting in
Sweden. The consent was documented in the research file of each
participant. The study was conducted according to the principles
expressed in the Declaration of Helsinki.
A total of 36 women were included. Twenty women were pre-
menopausal (aged 20–32 years) healthy volunteers with a body
mass index (BMI) of median 23.7 range 21–25.4. Of these 20
women, six were investigated in the follicular and luteal phases of
one menstrual cycle, five were investigated in two consecutive
luteal phases, and nine were investigated in one unexposed luteal
phase and one flaxseed exposed luteal phase. Five women were
healthy postmenopausal volunteers (aged 52–55 years, BMI
median 22.1 range 19.8–24.9) investigated at one time point.
Eleven women were postmenopausal (aged 58–78 years, BMI
median 23.4 range 21.3–32.7) and were treated for early breast
cancer. All patients had ER positive and/or PR positive tumors,
ten of the women had tumors sizes between10–19 mm with Elston
grade I–II and a negative sentinel node. One woman had a
25 mm Elston grade I tumor with one positive sentinel node and
25 unaffected lymphnodes in the axilla. All women had been off
sex steroid containing medication such as contraceptive methods
or hormone replacement therapy for more than three months.
The premenopausal women had a history of regular menstrual
cycles (cycle length 27–34 days) and had not used any antibiotics
within past three months.
Biopsies from human breast tissue were obtained from pre-
menopausal women, without ongoing hormonal treatment,
undergoing routine reduction mammoplasty.
Experimental design
All women were omnivore without any flaxseed in their daily
diet. The premenopausal women were investigated either in the
follicular and the luteal phase in one menstrual cycle or during two
consecutive luteal phases of two menstrual cycles. The luteinizing
hormone (LH) peak was determined in urine samples and
thereafter the first microdialysis investigation was performed
within 5–10 days. Of the twenty premenopausal women eleven
were controls and investigated either in one menstrual cycle or
during two consecutive luteal phases without diet modifications
whereas nine women added 25 g of freshly ground flaxseed/day to
their diet after the first microdialysis session. The next micro-
dialysis investigation was performed at the same day after the LH-
peak as in the first un-exposed cycle i.e. if the first microdialysis
was performed at day 5 after the LH-peak the next microdialysis
investigation was also performed at day 5. The five healthy
postmenopausal control women were investigated at one time
point.
The exposed postmenopausal women had been treated for early
breast cancer and tamoxifen 20 mg/day had been prescribed as
an adjuvant therapy. Tamoxifen treatment to early breast cancer
patients is a standard regimen in low risk patients in Sweden. All
had had a normal breast examination and mammography on the
contra-lateral side. Before the start of tamoxifen, microdialysis was
performed in the healthy breast and in subcutaneous fat. After six
weeks of tamoxifen treatment the women returned for the second
microdialysis.
As plasma and serum represent different compartments
compared with the extracellular space in tissues, and as they are
collected with another technique they are not ideal controls for
microdialysates. Therefore, microdialysis performed on abdominal
subcutaneous fat was used as an internal control. Additionally,
blood samples were collected at the start of each microdialysis
investigation.
Prior to insertion of the microdialysis catheters 0.5 ml lidocain
(10 mg/ml) was administrated intracutaneously. One microdia-
lysis catheter was placed in abdominal subcutaneous fat and one in
the upper lateral quadrant of the breast and directed towards the
nipple as previously described [4,26,27,28]. At the next micro-
dialysis investigation the catheters were inserted at the same
locations as in the previous session. The premenopausal women
and the postmenopausal controls were investigated in the left
breast whereas the women treated for breast cancer were
investigated in their healthy breast. A microdialysis catheter
(CMA 71/Microdialysis AB, Solna, Sweden), which consists of a
tubular dialysis membrane (20 mm long x 0.52 mm in diameter,
100,000 atomic mass cut-off) glued to the end of a double-lumen
tube (80 mm long x 0.8 mm in diameter), was used. The catheters
were inserted guided by a splitable introducer (CMA Microdialysis
AB). The catheters were connected to a microinfusion pump
(CMA 107, CMA/Microdialysis AB) and perfused with NaCl
154 mmol/L and hydroxyethyl starch 60 g/l (VoluvenH, Frese-
nius Kabi, Uppsala, Sweden), at a perfusion rate of 0.5 ml/min.
The solution entered the catheter through the outer tube and left it
through the inner tube, from which it was collected. After a 30-
min equilibration period, the outgoing perfusate containing
extracellular proteins was collected and stored at 270uC for
subsequent analysis.
Microdialysis is a sampling technique, which allows continuous
sampling of the extracellular fluid by passive diffusion of molecules
over a semi-permeable membrane. The recovery i.e. the amount
of substances from the tissue that diffuse into the perfusion fluid
depends on the membrane properties, the flow rate, tissue
temperature, and the size of the compound of interest. Diffusion
of low molecular substances over the dialysis membrane has been
shown to be almost complete at low flow rates using a 30 mm long
dialysis membrane [29]. However, for larger molecules the
recovery over the membrane decreases and the measured levels
in the microdialysis sample cannot be considered as the absolute
concentrations in the tissue. The recovery of a certain substance
may be measured in vitro by putting a microdialysis in a vial
containing the compound of interest, perfuse the catheter and
divide the concentration of the substance in the dialysate by the
concentration in the vial. The in vitro recovery of VEGF was 8%, of
angiogenin 31%, and of endostatin 33%. This in vitro recovery can
only be an estimate of the in vivo recovery since other factors such
as tissue pressure and temperature will affect the diffusion of
substances in vivo. Therefore, all microdialysis values are given as
original raw data without any re-calculations.
Breast tissue culture
Tissue biopsies containing epithelium, stroma, and adipose
tissue, were produced by using an 8 mm biopsy punch (Kai
Europe GmbH, Solingen, Germany) and placed in a 12-well plate
(Costar, Cambridge, MA, USA). Serum-free medium was used
consisting of a 1:1 mixture of nutrient mixture F-12 (GIBCO,
Angiogenesis Regulators in Breast Tissue In Vivo
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phenol red (GIBCO, Paisley, UK) supplemented with transferrin
(10 mg/ml; Sigma), insulin (1 mg/ml; Sigma), and bovine serum
albumin (0.2 mg/ml; Sigma) with or without physiological levels of
10
29 M estradiol (17b-estradiol; E2; Sigma), a combination of
10
29 M estradiol and 10
28 M progesterone (P4; Sigma) (E2 + P4),
or tamoxifen 10
26 M. The control group was incubated in media
supplemented with the vehicle, ethanol, equivalent to the hormone
treated groups (0.001%). The biopsies were treated for 7 days at
37uC in a humidified atmosphere containing 5% CO2 and the
medium was changed every day. After the seventh day of
incubation, the medium from each biopsy was collected and
stored at 270uC for subsequent analysis.
Determinations of estradiol, progesterone, VEGF,
angiogenin, and endostatin
Plasma was collected using a plastic tube containing spray dried
K2 EDTA as an anticoagulant, and were spun down and frozen at
270uC within 20 minutes of collection.
Microdialysates, plasma samples, and media from the breast
tissue biopsies, were analyzed using commercial quantitative
immunoassay kits; human endostatin (QuantikineH, R&D Sys-
tems, Minneapolis, MN), sensitivity 23 pg/ml and intra-assay
variation 3.7–6.9%, VEGF (QuantiGloH R&D Systems), sensitiv-
ity 3.3 pg/ml and intra-assay variation 2.8–7.9%, and Angiogenin
QuantikineH, R&D Systems), sensitivity 6 pg/ml and intra-assay
variation 2.8–3.3%. Estradiol and progesterone were analyzed
using ELISA kits from Calbiotech, Spring Valley, CA. The
sensitivity of the estradiol assay was 1.47 pmol/l and the intra-
assay variation 4.6–10%, and the sensitivity of the progesterone
assay was 0.7 nmol/l and the intra-assay variation 2–5.3%.
Lignan analyses
Serum samples were prepared for the analyses with a previously
described method [30] with slight modifications. Briefly, samples
were hydrolyzed at 37uC in 0.2 M sodium acetate buffer pH 5
containing 0.2 U/mL of b-glucuronidase and 2 U/mL of
sulphatase and extracted twice with diethyl ether. The extracts
Figure 1. Correlations of VEGF and estradiol. Microdialysis in normal breast tissue and abdominal subcutaneous fat was performed in five sets
of women; in follicular and luteal phases of six premenopausal women (12 investigations), in two consecutive luteal phases of five premenopausal
women (10 investigations in unexposed tissue), in nine premenopausal women before and after the addition of 25 g of ground flaxseed/day to their
diet, in five healthy postmenopausal women, and in 11 women before and after tamoxifen therapy as an adjuvant for early breast cancer (on two
women microdialysis was performed in breast tissue only). Estradiol and extracellular and plasma levels of VEGF are presented as raw data from
unexposed tissues. Open squares represent healthy postmenopausal women; open triangles represent postmenopausal women with previous breast
cancer. A. There were a significant positive correlation between extracellular VEGF in breast tissue and estradiol; r=0.6, p,0.001, n=47. B. There were
a significant positive correlation between extracellular VEGF in abdominal subcutaneous fat tissue and estradiol; r=0.4, p,0.01, n=45. C. There were
no correlation between plasma VEGF and estradiol, r=0.06, p=0.7, n=47.
doi:10.1371/journal.pone.0025720.g001
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with QAE-Sephadex A-25 in acetate form as earlier described
[31]. Chromatographic conditions for serum lignan analyses were
as described before [32]. The lignans in the batch of flaxseed used
were determined as previously described [33].
Statistics
Data are expressed as mean6SEM. Student’s t-test, ANOVA,
and Pearson’s correlation coefficient were used as appropriate. A
p,0.05 was considered as statistically significant.
Results
Characteristics of the subjects
There were no subsequent complications after the microdialysis
experiments.
The plasma estradiol levels of the six premenopausal investi-
gated in early follicular phase and luteal phase were 94620 pmol/
L and 322653 pmol/L respectively, n=6. The progesterone
levels increased from 1.960.3 nmol/L to 2668 nmol/L, n=6. In
the five premenopausal women investigated in two luteal phases
the plasma estradiol levels were 334645 pmol/L in the first luteal
phase and 314661 pmol/l in the second luteal phase, p=0.8,
n=5, and the progesterone levels were 1363.9 nmol/l and
1163 nmol/l respectively, p=0.5, n=5. In the flaxseed exposed
women the estradiol levels in the unexposed luteal phase were
392636 pmol/l and in the exposed cycle 425647 pmol/l, p=0.6,
n=9. The progesterone levels were 2063.4 nmol/l and
2463.8 nmol/L respectively, p=0.4, n=9. In the postmenopaus-
al control women the estradiol levels were 64612 pmol/L and the
progesterone levels 1.060.1 nmol/L, n=5. In the postmenopaus-
al women treated for breast cancer the levels before and after
tamoxifen treatment were 7965 pmol/l and 8464 pmol/l
respectively, p=0.5, n=11 and the progesterone levels
1.060.2 nmol/l and 0.760.2 nmol/l respectively, p=0.4,
n=11. The 25 g of flaxseed contained 44.32 mg of secoisolar-
iciresinol, 0.92 mg of pinoresinol, 0.46 mg of isolariciresinol,
0.40 mg of matairesinol, and 0.24 mg of lariciresinol.
Figure 2. Correlations of angiogenin and estradiol. Microdialysis in normal breast tissue and abdominal subcutaneous fat was performed in
five sets of women; in follicular and luteal phases of six premenopausal women (12 investigations), in two consecutive luteal phases of five
premenopausal women (10 investigations in unexposed tissue), in nine premenopausal women before and after the addition of 25 g of ground
flaxseed/day to their diet, in five healthy postmenopausal women, and in 11 women before and after tamoxifen therapy as an adjuvant for early
breast cancer (on two women microdialysis was performed in breast tissue only). Estradiol and extracellular and plasma levels of angiogenin are
presented as raw data from unexposed tissues. Open square represents healthy postmenopausal women; open triangle represents postmenopausal
women with previous breast cancer. A. There was a strong correlation between estradiol and extracellular breast angiogenin, r=0.81, p,0.0001,
n=47. B. There was a significant correlation between extracellular fat angiogenin and estradiol, r=0.6, p,0.0001, n=45. C. There were no correlation
between plasma angiogenin and estradiol, r=0.06, p=0.7, n=47.
doi:10.1371/journal.pone.0025720.g002
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To correlate extracellular levels of VEGF, angiogenin, and
endostatin with estradiol, data from unexposed tissues were
compared i.e. before start of tamoxifen treatment in the
postmenopausal women and in unexposed menstrual cycle in
the premenopausal flaxseed group, in the two unexposed luteal
phases as well as in the follicular and luteal phases of the
premenopausal controls, and in the five healthy postmenopausal
women. All premenopausal women and the postmenopausal
controls were investigated in both breast tissue and subcutaneous
fat whereas of the postmenopausal patients treated for breast
cancer, nine were investigated in both in the breast and the fat and
two women were investigated in breast tissue only. Hence, 47
microdialysis investigations in unexposed breast tissue and 45 in
unexposed fat tissue were performed.
VEGF
There was a wide inter-individual variation of VEGF levels in all
three compartments; breast and fat tissue and plasma. There were a
significant positive correlation between extracellular VEGF in breast
tissue as well as in fat tissue and estradiol levels; r=0.6, p,0.001,
n=47 in breast tissue, and r=0.4, p,0.01, n=45 in fat tissue,
Fig 1A–B. There were no correlation between plasma VEGF and
estradiol, r=0.06, p=0.7, n=47, Fig 1C. Plasma progesterone did
also correlate significantly with breast VEGF, r=0.46, p,0.001,
n=47andfatVEGF,r=0.35,p,0.01,n=45.Progesteronedidnot
correlate with extracellular plasma VEGF levels.
Angiogenin
There was a strong correlation between estradiol and extracel-
lular breast angiogenin, r=0.81, p,0.0001, n=47 and an equally
strong significant correlation between extracellular fat angiogenin
and estradiol, r=0.6, p,0.0001, n=45, Fig 2A–B. There were no
correlation between plasma angiogenin and estradiol, r=0.06,
p=0.7, n=47, Fig 2C. Plasma progesterone did also correlate
significantly with breast angiogenin, r=0.6, p,0.0001, n=47 and
extracellular fat angiogenin, r=0.47, p,0.001, n=45. Progester-
one did not correlate with plasma angiogenin levels.
Figure 3. Correlations of endostatin and estradiol. Microdialysis in normal breast tissue and abdominal subcutaneous fat was performed in five
sets of women; in follicular and luteal phases of six premenopausal women (12 investigations), in two consecutive luteal phases of five
premenopausal women (10 investigations in unexposed tissue), in nine premenopausal women before and after the addition of 25 g of ground
flaxseed/day to their diet, in five healthy postmenopausal women, and in 11 women before and after tamoxifen therapy as an adjuvant for early
breast cancer (on two women microdialysis was performed in breast tissue only). Estradiol and extracellular and plasma levels of angiogenin are
presented as raw data from unexposed tissues. Open square represents healthy postmenopausal women; open triangle represents postmenopausal
women with previous breast cancer. A. There was a significant negative correlation between extracellular endostatin levels in unexposed breast
tissue and plasma estradiol, r=20.6, p,0.0001, n=47. B. Extracellular fat endostatin and estradiol did not show a significant correlation, r=20.21,
p=0.17, n=45. C. There was no correlation between plasma endostatin and estradiol, r=20.19, p=0.19, n=47.
doi:10.1371/journal.pone.0025720.g003
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There was a significant negative correlation between extracel-
lular endostatin levels in unexposed breast tissue and plasma
estradiol, r=20.6, p,0.0001, n=47, Fig 3A. Extracellular fat
endostatin and estradiol did not show a significant correlation,
r=20.21, p=0.17, n=45, Fig 3B. There was no correlation
between plasma endostatin and estradiol, r=20.19, p=0.19,
n=47, Fig 3C. Plasma progesterone did also correlate significantly
with breast endostatin, r=20.46, p,0.001, n=47. Progesterone
did not correlate with extracellular fat or plasma endostatin levels.
Hormone exposure to breast tissue biopsies
To explore if sex steroids induced the alterations of the protein
levels observed in microdialysates and if tamoxifen had the ability
to alter the extracellular levels of these proteins whole breast tissue
biopsies from six different premenopausal women were cultured in
presence or absence of these compounds.
After exposure to estradiol VEGF and angiogenin levels
increased significantly while endostatin levels decreased, Fig 4
A–C. The addition of progesterone did not alter the change
compared with estradiol exposure alone, Fig 4A–C.
Tamoxifen decreased the levels of VEGF and angiogenin
significantly whereas the levels of endostatin increased by the
treatment, Fig. 4D–F.
In vivo treatments to subjects
Microdialysis was performed in three sets of women; in two
consecutive luteal phases of premenopausal women to investigate
the reproducibility of the protein measurements in microdialy-
sates; in premeopausal women before and after the addition of
flaxseed to their diet. To investigate the compliance in the flaxseed
exposed group of women we measured secoisolarisiresinol,
enterodiol, and enterolactone levels in serum; secoisolariciresinol
increased from non-detectable to 1468, enterodiol increased from
4.661.3 nmol/l to 85620 nmol/l, and enterolactone increased
from 2767 nmol/l to 189633 nmol/l confirming compliance
with the flaxseed addition. The third cohort of women was
patients before and after tamoxifen therapy as an adjuvant for
early breast cancer.
VEGF
In breast tissue, there was a significant increase of VEGF levels
in the luteal phase compared with the follicular phase of the
menstrual cycle whereas there were no differences in VEGF levels
in breast tissue in women investigated in two consecutive luteal
phases of the menstrual cycle, Fig 5A. No significant changes
were observed in fat tissue, Fig 5B. The addition of flaxseed did
not alter the levels significantly either in breast tissue or
subcutaneous fat, Fig 5C. Tamoxifen on the other hand
decreased the levels significantly both in breast tissue and
subcutaneous fat, Fig 5D.
Angiogenin
In breast tissue, there was a significant increase of angiogenin
levels in the luteal phase compared with the follicular phase of the
menstrual cycle whereas there were no differences in angiogenin
Figure 4. Hormone exposure of breast tissue biopsies ex vivo. Tissue biopsies from pre-menopausal women undergoing reduction
mammoplasties were cultured for seven days in serum-free medium supplemented with hormone solvent (C) or in the presence of estradiol (E2;
10
29 M), a combination of estradiol and progesterone to mimic the luteal phase of the menstrual cycle (E2+P4; 10
29 M and 10
28 M, respectively),
and tamoxifen (Tam 10
26 M). A. Estradiol alone and in combination with progesterone increased the levels of VEGF significantly, **p,0.01, n=5–6
biopsies in each group. B. Estradiol alone and in combination with progesterone increased the levels of angiogenin significantly, *p,0.05, n=5–6
biopsies in each group. C. Estradiol alone and in combination with progesterone decreased the levels of endostatin significantly, *p,0.05, n=5–6
biopsies in each group. D. Tamoxifen decreased the levels of VEGF significantly, ***p,0.001, n=5–7 biopsies in each group. E. Tamoxifen decreased
the levels of angiogenin significantly, *p,0.05, n=5–7 biopsies in each group. F. Tamoxifen increased the levels of endostatin significantly, **p,0.01,
n=5–7 biopsies in each group.
doi:10.1371/journal.pone.0025720.g004
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luteal phases of the menstrual cycle, Fig 6A. No significant changes
were observed in fat tissue, Fig 6B. The addition of flaxseed did
not alter the levels significantly either in breast tissue or
subcutaneous fat, Fig 6C. There was a significant decrease of
extracellular angiogenin levels of the normal breast after tamoxifen
therapy but not in subcutaneous fat, Fig 6D.
Endostatin
In breast tissue, there was a significant decrease of endostatin
levels in the luteal phase compared with the follicular phase,
whereas there were no differences in endostatin levels in breast
tissue in women investigated in two consecutive luteal phases of
the menstrual cycle, Fig 7A. No significant changes were
observed in fat tissue, Fig 7B. The addition of flaxseed did
increase the levels of endostatin significantly in breast tissue,
Fig 7C. However, the tissue endostatin levels did not correlate
with serum lignan concentrations e.g. enterodiol, enterolactone,
or enterodiol + enterolactone. After tamoxifen the levels of
endostatin increased significantly both in breast tissue and
subcutaneous fat, Fig 7D.
Discussion
Here we show that one of the most potent endogenous
angiogenesis inhibitor, endostatin, exhibit a negative correlation
with estradiol in normal human breast tissue in situ. This was
confirmed in cultured normal breast tissue biopsies where estradiol
exposure decreased the endostatin levels whereas addition of
progesterone did not alter endostatin levels compared with
estradiol exposure alone. Tamoxifen increased the endostatin
levels both in women in vivo and in cultured breast biopsies. In a
similar fashion as tamoxifen, a diet of flaxseed to healthy
premenopausal women increased the extracellular endostatin in
breast tissue significantly.
As previously reported from our group [4,5,12], two of the most
potent endogenous pro-angiogenic factors, extracellular VEGF
and angiogenin, exhibited a significant correlation with estradiol in
Figure 5. Extracellular VEGF levels in vivo. Microdialysis in normal breast tissue and abdominal subcutaneous fat was performed in five sets of
women; in follicular and luteal phases of six premenopausal women, in two consecutive luteal phases of five premenopausal women, in nine
premenopausal women before and after the addition of 25 g of ground flaxseed/day to their diet, in five healthy postmenopausal women, and in 11
women before and after tamoxifen therapy as an adjuvant for early breast cancer (on two women microdialysis was performed in breast tissue only).
A. There were no changes in extracellular VEGF levels in breast tissue of healthy postmenopausal women and premenopausal women in the follicular
phase. VEGF increased significantly in the luteal phase compared to the follicular phase, **p,0.01, n=6. There were no change during the two
consecutive luteal phases, n=5. B. There were no significant changes in extracellular VEGF in fat tissue. C. There were no significant changes in
extracellular breast or fat VEGF levels in the luteal phase after flaxseed supplementation, n=9. D. Extracellular breast levels of VEGF decreased
significantly after six weeks of tamoxifen treatment, *p,0.05, n=11. As did also the extracellular fat VEGF levels after the treatment period, *p,0.05,
n=9. Inset shows re-scaled tamoxifen data.
doi:10.1371/journal.pone.0025720.g005
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biopsies confirmed an estrogen dependent expression of these
proteins. Even though the in vivo levels of the proteins in breast
tissue exhibited significant correlations with progesterone levels the
breast biopsy experiment showed that progesterone had no
additional effect compared to estradiol exposure alone. Tamoxifen
significantly decreased the levels of VEGF and angiogenin in
normal breast tissue both in microdialysates of women and in
media of cultured breast tissue biopsies. A diet of flaxseed did,
however, not alter VEGF or angiogenin in the breast.
Estrogens have been shown to regulate angiogenesis in
experimental breast cancer, but very few studies have investigated
the regulation of angiogenesis in the normal human breast [5,7,8].
One reason has been a lack of suitable techniques and models for
this research. Microdialysis is a minimally invasive technique,
which enables sampling of molecules in the extracellular space in
situ of normal breast and whole breast tissue culture enables studies
of the biology of the breast as an organ ex vivo [18,34,35,36]. The
extracellular space is the bioactive site for the majority of
angiogenic factors as a result of the release and/or cleavage of
larger proteins into anti-angiogenic fragments. For example,
endostatin is cleaved in the extracellular space from collagen
XVIII. Due to this post-translational activation/release mRNA
levels or intracellular protein levels will not reflect bioactive
protein levels as we previously have shown regarding the VEGF
regulation [37]. Moreover, as in the case of endostatin, antibodies
raised against cleaved proteins may cross-react with the primary
molecule, in the case of endostatin, collagen XVIII. By using
microdialysis sampling of proteins from their bioactive site with a
membrane cut-off level that excludes larger original proteins only
the cleaved bioactive fragment is sampled. One of the strengths in
this study is that a direct measurement of the proteins in live tissue
is used and in a unique manner quantifies proteins direct in the
target organ.
A tipping of the angiogenic balance to favor a pro-angiogenic
environment is a key event in the initiation, growth, and
progression of tumors. At autopsy it has been found that up to
fifteen percent of all women present in situ tumors in their breast
whereas only 1% of women in the same age range are diagnosed
with breast cancer [38]. An angiogenic switch may convert this
Figure 6. Extracellular angiogenin levels in vivo. Microdialysis in normal breast tissue and abdominal subcutaneous fat was performed in five
sets of women; in follicular and luteal phases of six premenopausal women, in two consecutive luteal phases of five premenopausal women, in nine
premenopausal women before and after the addition of 25 g of ground flaxseed/day to their diet, in five healthy postmenopausal women, and in 11
women before and after tamoxifen therapy as an adjuvant for early breast cancer (on two women microdialysis was performed in breast tissue only).
A. There were no changes in extracellular Angiogenin levels in breast tissue of healthy postmenopausal women and premenopausal women in the
follicular phase. Angiogenin increased significantly in the luteal phase compared to the follicular phase, ***p,0.0001, n=6. There were no change
during the two consecutive luteal phases, n=5. B. There were no significant changes in extracellular Angiogenin in fat tissue. C. There were no
significant changes in extracellular breast or fat angiogenin levels in the luteal phase after flaxseed supplementation, n=9. D. Extracellular breast
levels of angiogenin decreased significantly after six weeks of tamoxifen treatment, **p,0.01, n=11. There were no changes in extracellular fat
angiogenin after the treatment period, n=9.
doi:10.1371/journal.pone.0025720.g006
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disease. It has long been known that exposure to sex steroids
increase the risk of breast cancer while early oophorectomy may
reduce the risk of this disease by up to 60% [39,40]. Ovarian
ablation is, however, associated with osteoporosis and cardiovascu-
lar disease as well as vasomotor symptoms, urogenital atrophy, and
decrease quality of life. Tamoxifen has been shown to reduce the
incidenceofbreast cancerbymore than 40% buttamoxifentherapy
may induce severe side effects such as endometrial cancer and
thromboembolism [20,41]. Clearly there is a need to develop safer
and less toxic breast cancer preventive strategies.
In our present data tamoxifen had significant effects on the pro-
angiogenic proteins investigated here. Both angiogenin and VEGF
levels were 22–25% lower in breast tissue after tamoxifen therapy
for six weeks. Overall there were very low levels of VEGF in breast
tissue, 5–80 pg/ml compared with angiogenin levels in the range
of 3490–10300 pg/ml, and endostatin concentrations varying
between 5721–15480 pg/ml in unexposed breast tissue. Although
the in vitro recovery was approximately four times lower for VEGF
this do not explain the differences in the tissue, hence the absolute
levels for VEGF are much lower than those of the other proteins.
As VEGF and angiogenin induce in vivo blood vessel growth at
similar concentrations [9,42] the higher angiogenin concentrations
may be a physiologically more important pro-angiogenic factor in
situ and a clinically more important factor to target.
Tamoxifen did also increase the endostatin levels by 33% in
breast tissue. Clinical trials using recombinant endostatin for
cancer therapy have failed for patients in an advanced stage [43].
Although endostatin yet has to be proven efficient for cancer
therapy the significance of this protein may be in prevention of
cancer. Individuals with endogenous higher endostatin levels due
to increased copy numbers of the gene coding for collagen XVIII
have reduced risk of solid tumors [44] and endostatin deficient
mice exhibit decreased tumor growth rate compared with wild-
type mice [45].
Diet modifications may be another route for breast cancer
prevention associated with less side-effects compared with drugs
such as tamoxifen. We have recently shown that a diet of 10%
flaxseed to mice bearing estrogen dependent breast cancer
explants reduces growth and angiogenesis by affecting angiogen-
esis regulators including VEGF [46,47,48]. Moreover, a daily
addition of 25 g of flaxseed for 30 days to postmenopausal women
Figure 7. Extracellular endostatin levels in vivo. Microdialysis in normal breast tissue and abdominal subcutaneous fat was performed in five
sets of women; in follicular and luteal phases of six premenopausal women, in two consecutive luteal phases of five premenopausal women, in nine
premenopausal women before and after the addition of 25 g of ground flaxseed/day to their diet, in five healthy postmenopausal women, and in 11
women before and after tamoxifen therapy as an adjuvant for early breast cancer (on two women microdialysis was performed in breast tissue only).
A. There were no changes in extracellular Endostatin levels in breast tissue of healthy postmenopausal women and premenopausal women in the
follicular phase. Endostatin decreased significantly in the luteal phase compared to the follicular phase, ***p,0.0001, n=6. There were no change
during the two consecutive luteal phases, n=5. B. There were no significant changes in extracellular Endostatin in fat tissue. C. There were a
significant increase of the extracellular breast endostatin levels in the luteal phase after flaxseed supplementation, **p,0.01, n=9. The levels of
endostatin in fat tissue did not change after a diet of flaxseed. D. Extracellular breast levels of endostatin increased significantly after six weekso f
tamoxifen treatment, **p,0.01, n=11. The levels of endostatin in fat tissue did also increase after the treatment period, *p,0.05 n=9.
doi:10.1371/journal.pone.0025720.g007
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several biological tumor markers [49].
In this study we wanted to investigate if anti-angiogenic effects
similar to that of tamoxifen could be induced by dietary flaxseed in
healthy volunteers. Our present data did, however, not show any
effects of VEGF levels in breast tissue after the addition of flaxseed
to the diet. The difference compared with the animal data, where
VEGF levels decreased by flaxseed, may be a difference of
cancerous tissue versus normal tissue and the fact that there is a
magnitude of difference in lignan exposure in women (,1 mg/kg
bwt) and mice (,10 mg/kg bwt). Moreover, in animal studies, the
amount of flaxseed added to the diet equates approximately 10%
of the daily caloric intake while in women 25 g of ground flaxseed
is less than 5% of the total calorie intake. However, in humans,
continuous flaxseed ingestion above 30 g/day is not recommended
due to the presence of endogeneous cyanogenic compounds in
seeds and the plant’s disposition to accumulate cadmium from soil.
The total lignan content in the flaxseed used in our study was
equal to levels previously reported [50]. There are several
metabolically active components in flaxseed and it has been
reported that flaxseed may affect estrogen metabolism in
postmenopausal women [51]. In our study we were not able to
detect any differences in estradiol and/or progesterone levels after
flaxseed ingestion in the women ruling out an effect of flaxseed on
estrogen levels in our data. The levels of enterodiol and
enterolactone after flaxseed ingestion confirmed the compliance
with the diet. However, there were no significant correlation
between serum levels of secoisolariciresinol, enterodiol, enterolac-
tone or the total enterolignan levels and endostatin in breast tissue.
This may suggest that there is no strong dose-response relationship
with endostatin and lignans, or the cohort is to small to detect a
possible relationship or, that other component(s) in flaxseed, not
measured in our study, may modulate endostatin in breast tissue.
In summary, this study shows for the first time that extracellular
levels of endostatin in normal human breast tissue in vivo exhibited
a significant negative correlation with estradiol. Tamoxifen
decreased the pro-angiogenic factors angiogenin and VEGF, and
increased the levels of the anti-angiogenic endostatin in normal
breast tissue. An addition of 25 grams of ground flaxseed to
healthy volunteers during one menstrual cycle did not affect the
levels of angiogenin and VEGF in normal breast tissue but
increased the levels of endostatin in a similar fashion as tamoxifen.
These results reveal previously unknown mechanisms of tamoxifen
in the normal breast. A diet modification with flaxseed for one
menstrual cycle does not seem to be equally powerful as tamoxifen
in tipping the angiogenic balance towards angiogenesis inhibition
in normal breast tissue. Further studies of diet alterations, perhaps
of a longer duration, for elucidating effects on normal breast tissue
for breast cancer prevention are warranted.
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